Fig. 6: Adjuvant OV vaccination against Muts improves outcome. | Nature Communications

Fig. 6: Adjuvant OV vaccination against Muts improves outcome.

From: Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Fig. 6

a Treatment schedule used in this study. b Mice bearing established SC B16F10 tumors were treated IM with polyI:C and the indicated peptide on days 7 and 14 post-tumor seeding. All tumors were measured on day 21. The tumor volumes are expressed as relative to the average tumor volume of control mice (treated with polyI:C only) (from left to right; n = 5, 10, 10, 4, 10, 15 and 10). NS: p > 0.05, ***: p < 0.001 (unpaired two-tailed t-test). c IFNγ ELISPOT (n = 5) and (d) Kaplan–Meier survival analysis (n = 10) of B16F10 lung tumor-bearing mice treated with Ad and MRB or Ad and MRB co-administered with B16Mut20, B16Mut30, B16Mut44 and B16Mut48. ELISPOT: NS: p > 0.05, ***: p < 0.001 (unpaired two-tailed t-test) and survival: NS: p > 0.05, ***: p < 0.001 (Mantel–Cox test, two-sided). e Mice bearing established SC CT26 tumors were treated and analyzed as in (b) (from left to right; n = 9, 5, 5, 10 and 10). NS: p > 0.05, *: p < 0.05 (unpaired two-tailed t-test). f IFNγ ELISPOT (n = 5) and (g) Kaplan–Meier survival analysis (n = 10) of SC CT26 tumor-bearing mice treated on days 7 and 14 post-tumor seeding with Ad and MRB or Ad and MRB co-administered with CT26Mut20, CT26Mut27 and CT26Mut37. ELISPOT: NS: p > 0.05, ***: p < 0.001 (unpaired two-tailed t-test) and survival: NS: p > 0.05, ***: p < 0.001 (Mantel–Cox test, two-sided). Source data are provided as a Source Data file. Exact p values can be found in the Source Data.

Back to article page